*ST恆康(002219.SZ):新里程為恆康醫療重整投資人、中民醫療為備選重整投資人
格隆匯12月8日丨*ST恆康(002219.SZ)公佈,2021年12月1日,管理人在隴南中院多功能廳組織召開了重整投資人遴選評審會,兩家參選的投資人通過視頻會議逐一進行陳述,並回答評審委員的提問。評審委員來自債權人代表、股東代表、職工代表及外部行業專家代表,共13名。經評審委員投票,新里程獲得7票,中民醫療獲得6票。根據評審規則,新里程為恆康醫療重整投資人,中民醫療為備選重整投資人。
在隴南中院的指導監督下,管理人正與新里程協商簽署重整投資協議等相關文件,管理人將及時公吿協議簽署進展情況,並持續推進破產重整相關工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.